Short Interest in Capstone Therapeutics Corp. (NASDAQ:CAPS) Grows By 210.7%

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the target of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 321,408 shares, an increase of 210.7% from the May 14th total of 103,447 shares. Currently, 4.2% of the company’s shares are short sold. Based on an average daily trading volume, of 14,882,138 shares, the short-interest ratio is currently 0.0 days.

Hedge Funds Weigh In On Capstone Therapeutics

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC acquired a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 2.55% of the company’s stock.

Capstone Therapeutics Price Performance

CAPS stock opened at $0.30 on Friday. The firm has a market cap of $3.72 million, a price-to-earnings ratio of -0.09 and a beta of -1.54. The company has a quick ratio of 0.29, a current ratio of 0.95 and a debt-to-equity ratio of 0.79. Capstone Therapeutics has a 12-month low of $0.26 and a 12-month high of $2.07. The company’s fifty day simple moving average is $0.39 and its 200 day simple moving average is $0.59.

Capstone Therapeutics (NASDAQ:CAPS) last released its earnings results on Wednesday, May 20th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $12.64 million during the quarter, compared to analyst estimates of $10.80 million. Capstone Therapeutics had a negative net margin of 41.26% and a negative return on equity of 114.15%.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, June 3rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Capstone Therapeutics presently has an average rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.